Bachem Holding AG (BCHMY) Q2 2026 Earnings Call Transcript
Bachem Holding AG (BCHMY) Q4 2025 Earnings Call Transcript
| Chemicals Industry | Materials Sector | Mr. Thomas Meier CEO | OTC PINK Exchange | CH0012530207 ISIN |
| Switzerland Country | 2,009 Employees | 5 May 2026 Last Dividend | - Last Split | - IPO Date |
Bachem Holding AG is a global leader in the pharmaceutical and biotechnology sectors, offering a wide range of products and services for research, clinical development, and commercial application. The company specializes in the development, production, and regulatory support of peptide active pharmaceutical ingredients (APIs), including peptide and oligonucleotide new chemical entities (NCEs). Founded in 1971, Bachem has established its headquarters in Bubendorf, Switzerland, and has since been committed to providing high-quality solutions to its clients worldwide.
Specializing in the development and production of NCEs, Bachem offers cutting-edge solution for pharmaceutical and biotechnology companies focusing on peptide and oligonucleotide-based drugs. This includes both research and commercial scale products.
Bachem supplies a range of commercially available NCEs and generic APIs, catering to the ongoing needs of the healthcare industry for reliable and effective ingredients.
The company provides comprehensive project management services, ensuring efficient and timely execution of drug development projects from concept through to commercialization.
Bachem offers in-depth quality and regulatory support to help clients navigate the complex drug approval processes, ensuring compliance with all applicable regulations and guidelines.
With its advanced analytical services, Bachem supports the accurate and precise measurement of pharmaceutical compounds, ensuring they meet the stringent quality standards required in the industry.
Bachem’s GMP production services are aligned with international standards, providing clients with high-quality peptides and oligonucleotides suitable for clinical trials and commercial applications.
The company also offers research grade production services, supplying peptides and oligonucleotides for preclinical and early-stage drug development research.
Bachem's supply and vertical integration services ensure the seamless procurement and integration of raw materials, intermediates, and APIs for pharmaceutical and biotech companies, optimizing the supply chain and reducing time to market.